MedPath

Prognostic Value of Surem TRAF3IP2 Level in Patients With Acute Myocardial Infarction

Recruiting
Conditions
Myocardial Infarction, Acute
Registration Number
NCT06038994
Lead Sponsor
Nanjing Medical University
Brief Summary

To evaluate the prognostic value of surem TRAF3IP2 levels in patients with acute myocardial infarction

Detailed Description

Previous study had concluded that TRAF3IP2 plays a causal role in atherosclerotic plaque development and vulnerability in mice. However, no human data was available. In the present study, patients diagnosed with acute myocardial infarction who receive coronary angiography will be enrolled. Their surem TRAF3IP2 levels will be tested using ELASA. The association of surem TRAF3IP2 levels with the major adverse cardiac events will be evaluated.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  1. Patients with acute myocardial infarction
  2. patients received coronary angiography
  3. invasive management within 72 h of hospital admission
Exclusion Criteria
  1. NYHA III-IV
  2. malignant tumor
  3. acute infection
  4. thyroid dysfunction
  5. Life expectancy of b1 y
  6. Unsuitable for PCI

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
MACEs (major adverse cardiac events)1 year

MACEs were defined as a composite of cardiac death, hospitalization for myocardial infarction or heart failure

Secondary Outcome Measures
NameTimeMethod
hospitalization for myocardial infarction or heart failure1 year

hospitalization for myocardial infarction or heart failure

cardiac death1 year

and death due to cardiac reasons, such as myocardial infarction or heart failure

Trial Locations

Locations (1)

Huai'an First People's Hospital

🇨🇳

Huai'an, Jiangsu, China

Huai'an First People's Hospital
🇨🇳Huai'an, Jiangsu, China
Xiaozhong Yang, MD.
Contact
+8684922412

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.